NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.

Workspace · Cancer algorithms · Ovary

Ovary

Ovary · 21,010 new · 12,450 deaths (ACS 2026) · mortality 5.7 per 100k · 5-yr RS 52% (SEER)

Mortality 5.7 per 100k (SEER / ACS common-sites). Never an artboard percent.

254,621 women living with ovarian cancer in 2023 (SEER Stat Facts). Lifetime is not restated here — it collides with a locked artboard figure. No encoded screening interval. Not a CA-125 engine.

254,621 women living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.

Median age at diagnosis 63 · at death 71 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.

Incidence women 10.4 per 100k · mortality women 5.7 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.

Most often diagnosed among women aged 55–64. Deaths highest among women aged 65–74. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.

New cases falling 1.4% each year (2014–2023). Death rates falling 2.9% each year (2015–2024). Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval. Not a CA-125 engine.

Highest new-case rate: Non-Hispanic American Indian/Alaska Native women 11.3 per 100k. Highest death rate: Non-Hispanic American Indian/Alaska Native women 6.4 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank. Not a CA-125 engine.

Race/ethnicity rates per 100k (SEER Stat Facts)

SEER Stat Facts race and ethnicity incidence and mortality per 100k
Group	Inc. men	Inc. women	Deaths men	Deaths women
Hispanic	—	10.5	—	4.7
Non-Hispanic American Indian/Alaska Native	—	11.3	—	6.4
Non-Hispanic Asian/Pacific Islander	—	9.8	—	4.2
Non-Hispanic Black	—	9.4	—	5.2
Non-Hispanic White	—	10.5	—	6.0

Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank. Not a CA-125 engine.

USPSTF screening pointer

USPSTF 2018 D · Asymptomatic women without a known high-risk hereditary cancer syndrome · Do not screen — CA-125 / TVUS are not an engine here

Cited only. No screening interval and no unpublished coefficient. USPSTF-ovary-2018

ACS early-detection pointer

ACS 2026 · Women without symptoms or high risk · ACS (2026): there are no recommended screening tests for ovarian cancer for women without symptoms or high risk. TVUS and CA-125 are named as tests that do not lower ovarian-cancer deaths when used to screen average-risk women. Complementary to the cited USPSTF 2018 D statement. Not a CA-125 or TVUS engine.

Cited ACS statement only. Not a screening engine. ACS-ovary-detect

USPSTF risk-assessment pointer

USPSTF 2019 B/D · Women — familial risk assessment, not ovarian screening · USPSTF 2019 BRCA-related risk-assessment statement (Grade B/D) is about familial risk tools and counseling, not ovarian cancer screening. Average-risk ovarian screening remains Grade D (2018). No CA-125 engine is encoded. Named tools are not encoded. Tyrer-Cuzick remains needs-license.

Cited familial-risk statement only. Not a screening interval and not a scoring engine. USPSTF-brca-2019

Surveillance pointer

ACS-ovary-follow 2025 · cited only · ACS after-treatment page: follow-up visits may include exams, lab tests, or scans. CA-125 is named as a marker sometimes used to check for recurrence; ACS says it is not clear that treating on CA-125 before symptoms helps people live longer. Not a CA-125 surveillance engine. Those months are not encoded.

Named public source only. Not a personal follow-up calendar. ACS-ovary-follow

Surveillance pointer

ACS-ovary-after 2025 · cited only · ACS after-treatment page names later cancers after ovarian-cancer treatment, including colorectal, small intestine, renal pelvis, breast, bladder, bile duct, eye melanoma, acute leukemia after some chemo, and soft tissue after radiation. Lynch and BRCA are named, not encoded. Complementary to the living-as pointer. Official lifetime figures are not restated. Not a CA-125 or second-primary screening engine.

Named public source only. Not a personal follow-up calendar. ACS-ovary-after

Surveillance pointer

ACS-long-term-effects 2025 · cited only · ACS long-term page names low estrogen after oophorectomy, pelvic radiation, or hormone-blocking medicines, plus osteopenia or osteoporosis and lymphedema after node surgery or radiation. Those names are not encoded. Complementary to the living-as pointer. Official lifetime figures are not restated. Not a CA-125, DXA-interval, or hormone engine.

Named public source only. Not a personal follow-up calendar. ACS-long-term-effects

Surveillance pointer

ACS-follow-up-care 2025 · cited only · ACS follow-up-care page names a treatment summary and survivorship care plan, plus watching for recurrence and for a second cancer. Regular cervical or breast screening may be named. Those plans and screens are not encoded. Complementary to the GYN printout. Official lifetime figures are not restated. GTD stays out of domain. Not a CA-125 engine.

Named public source only. Not a personal follow-up calendar. ACS-follow-up-care

Toxicity pointer

ACS-ovary-follow 2025 · empty on purpose · ACS after-treatment page names long-term treatment side effects. Those late effects are not encoded. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-ovary-follow

Toxicity pointer

ACS-ovary-after 2025 · empty on purpose · ACS after-treatment page names later cancers after ovarian-cancer treatment. Those second-cancer risks are not encoded. Official lifetime figures are not restated. Complementary to the living-as pointer. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-ovary-after

Toxicity pointer

ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later low estrogen, osteoporosis, and lymphedema after pelvic treatment or node surgery. Those late effects are not encoded. Official lifetime figures are not restated. Complementary to the empty-on-purpose first pointer. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-long-term-effects

Toxicity pointer

ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names a treatment summary and second-cancer watching after pelvis treatment. Those named tests are not encoded. Official lifetime figures are not restated. Complementary to the GYN printout. GTD stays out of domain. First-row ovary toxicity stays empty on purpose. Not a CA-125 engine. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-follow-up-care

Late toxicity printout

Late toxicity printout — GYN

Acute: ACS names fatigue, pelvic-field skin change, short-term rectal and bladder problems, nausea, and vaginal or vulvar field irritation. Late: radiation proctitis and cystitis, incontinence, fistula, menopause symptoms, fertility effects, low estrogen, osteoporosis, lymphedema, lasting fatigue, jaw osteonecrosis after bisphosphonates, and vision change after hormone therapy. Monitor: pelvic bleeding, pain, or leakage after RT; regular cervical screening may be named; lasting fatigue or sleep problems; dental check before bisphosphonates; vision change after hormone therapy; a treatment summary. Those names are not encoded. GTD stays out of domain. First-row cervix toxicity stays empty on purpose. Not a CA-125, HPV-dose, or ASCCP engine.

Questions to ask

ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.

ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.

ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.

Treatment summary and care plan

ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.

How late effects are managed

ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.

ACS long-term late names

Low estrogen after pelvic treatment
Osteoporosis after hormone-affecting treatment
Low estrogen or testosterone after hormone-affecting treatment
Osteonecrosis of the jaw after bisphosphonates
Vision change after hormone therapy
Lymphedema after pelvic-node surgery or RT
Cancer-related fatigue that lasts
Joint or muscle pain after some treatments
Mental health and distress after treatment

Named conditions to monitor

Pelvic bleeding, pain, or leakage after RT
Menopause symptoms
Cervix first-row toxicity
Bone density after hormone-affecting treatment
Hot flashes, bone loss, or sex-hormone change after hormone-affecting treatment
Dental check before bisphosphonates
Vision change after hormone therapy
Cancer-related fatigue or sleep problems that last
Joint or muscle pain after chemo, steroids, or hormone therapy
Anxiety, depression, or fear of recurrence after treatment
Second-cancer awareness after radiation or chemo
Ask which late-effect tests belong on the follow-up plan

Acute toxicities · Late toxicities · Named conditions to monitor. Cadences are placeholders. Named tests are not encoded. Adult GYN RT fields only. Gestational trophoblastic disease is out of domain. Complementary ACS long-term page is named, not encoded. Not a CA-125 or ASCCP engine. No invented trial percent.

Open GYN printout →

NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.

algo-stub-ovary · stub · none · v2-stub-ovary

SEER 5-year relative survival by stage (cited stub)

Localized 91.9% · Regional 70.1% · Distant 31.5% · All 52.0%

Lifetime is not restated here — it collides with a locked artboard figure. Not a CA-125 engine.

Percent of cases by stage (SEER Stat Facts)

Localized 22% · Regional 18% · Distant 54% · Unknown 6%

Percent of cases at diagnosis — not 5-year relative survival. SEER Combined Summary Stage. Lifetime is not restated here. Not a CA-125 engine.

Screening · Surveillance · Toxicity on four golden fixtures

Rio · Plan — survivor

not computed — v2 stub

Cited ACS/SEER population pin only

screening
USPSTF 2018 D — do not screen average-risk ovary
Cited USPSTF 2018 D, ACS 2026, and the 2019 BRCA familial-risk statement. Not a CA-125 / TVUS engine.
not encoded
surveillance
ACS follow-up cited — CA-125 months not encoded
Cited ACS after-treatment page only. Not a CA-125 surveillance engine.
not encoded
toxicity
ACS late effects cited — ovary months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Noah · Plan — skin cancer

not computed — v2 stub

Cited ACS/SEER population pin only

screening
USPSTF 2018 D — do not screen average-risk ovary
Cited USPSTF 2018 D, ACS 2026, and the 2019 BRCA familial-risk statement. Not a CA-125 / TVUS engine.
not encoded
surveillance
ACS follow-up cited — CA-125 months not encoded
Cited ACS after-treatment page only. Not a CA-125 surveillance engine.
not encoded
toxicity
ACS late effects cited — ovary months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Walter · S1 prostate

not computed — v2 stub

Cited ACS/SEER population pin only

screening
USPSTF 2018 D — do not screen average-risk ovary
Cited USPSTF 2018 D, ACS 2026, and the 2019 BRCA familial-risk statement. Not a CA-125 / TVUS engine.
not encoded
surveillance
ACS follow-up cited — CA-125 months not encoded
Cited ACS after-treatment page only. Not a CA-125 surveillance engine.
not encoded
toxicity
ACS late effects cited — ovary months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Priya · average-risk

not computed — v2 stub

Cited ACS/SEER population pin only

screening
USPSTF 2018 D — do not screen average-risk ovary
Cited USPSTF 2018 D, ACS 2026, and the 2019 BRCA familial-risk statement. Not a CA-125 / TVUS engine.
not encoded
surveillance
ACS follow-up cited — CA-125 months not encoded
Cited ACS after-treatment page only. Not a CA-125 surveillance engine.
not encoded
toxicity
ACS late effects cited — ovary months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Not implemented. Cited public snapshot only. Not a screening recommendation. Mortality is a rate per 100k, not an artboard percent.

All cancers →Screening →Surveillance →Toxicity →